NEW YORK, June 1, 2011 /PRNewswire/ -- Investor Uprising (www.investoruprising.com) has released "A Guide to Biotech Investing," a four-page, definitive guide to the best biotech Exchange Traded Funds (ETFs) and mutual funds, which is available free to registered users of the Website.
"A Guide to Biotech Investing" analyzes the ongoing biotech bull market, identifying the leading biotech mutual funds and ETFs. It explains how individual investors can gain exposure to the biotech market to diversify their portfolios, as well as how to go about looking at a variety of biotech funds and ETFs.
"Biotech has been roaring forward, and not a lot of investors are aware of how to gain exposure to the market," says R. Scott Raynovich, editor-in-chief, Investor Uprising. "Biotech ETFs are a good play in an appealing investment sector with relatively low correlation to macro-economic problems."
Some biotech funds identified in the report are up more than 100% over the last five years, with less volatility than the Nasdaq Index. This report tells you why, and how to tell the funds apart. The report explains the components of the various biotech ETFs and which should be sought for either large-cap or mid-cap investments. The report compares the leading biotech funds and ETFs with leading technology ETFs.
The mutual funds and ETFs tracked by the report include the T. Rowe Price Health Sciences Fund (PRHSX), Fidelity Select Biotechnology fund (FBIOX), BlackRock Health Sciences Ops Inv A (SHSAX), Vanguard Healthcare ETF (VHT), First Trust NYSE Arca Biotech Index (NYSE: FBT), iShares Nasdaq Biotechnology Index (Nasdaq: IBB), and the SPDR S&P Biotech ETF (NYSE: XBI).
The report is the secon
|SOURCE Investor Uprising|
Copyright©2010 PR Newswire.
All rights reserved